TORONTO, Sept. 26, 2018 /CNW/ - Beleave Inc. (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") is pleased to announce it has amended its non-exclusive investment agreement with Alumina Partners, LLC, a New York-based private investment partnership, providing the availability of up to CAD $30 million (previously CAD $20 million) over a 24-month period, to take advantage of new opportunities, increase operating flexibility, and strengthen the Company's balance sheet.
Pursuant to the terms of the amended agreement, Alumina Partners will increase its commitment to purchase up to CAD $30 million (previously CAD $20 million) units of the Company, consisting of one common share and one common share purchase warrant. The unit price will be determined within the regulatory issuance maximum discount of up to 20% (previously up to 25%) of the share price at the time of drawdown. Each offering occurring exclusively at the option of the Company throughout the term of the agreement. The exercise price of the warrants will be at a 50% premium (previously 25%) over the market price at time of issuance.
"This agreement provides compelling value and liquidity to our shareholders" said Andrew Wnek, Beleave CEO. "We've increased the available access to capital while securing terms that are more advantageous to Beleave."
EXECUTIVE MANAGEMENT UPDATE The company also announced executive management changes that will encourage increased collaboration between the Company's expanding operations. As part of these changes, Andrew Wnek and Bojan Krasic have been appointed to new positions within the Company as they expand the scope of their responsibilities.
Andrew Wnek has been appointed as Chairman by the Board of Directors. Mr. Wnek joined the Board in December 2015 and was appointed CEO of Beleave in October 2017. His appointment as Chairman provides continuity in the newly restructured Board as it seeks to take advantage of new and developing opportunities in the evolving cannabis industry.
"We are in one of the most exciting periods of innovation and change in Canada's history, and Beleave plays an active part in that story thanks to our relentless focus and strong leadership," said Wnek. "I thank the Board for this appointment and look forward to working together on everything that lies ahead as we implement our growth strategy for 2019 and beyond."
Along with Andrew Wnek's appointment, the Company also announced that current CFO Bojan Krasic will have additional responsibilities in his newly appointed role as President and CFO of the Company. Mr. Krasic joined Beleave in early 2013 and has been integrally involved in developing the Company's partnerships and instrumental in raising capital to fund new opportunities, increasing operating flexibility, and strengthening the Company's balance sheet. In his expanded role, Mr. Krasic will also provide leadership to the sales, marketing, and retail teams, while providing operational oversight to the Company's increasing production and scientific research operations.
Beleave also announced that it has granted 200,000 stock options to purchase common shares to each Mark Heselton and Mark Miles, appointed Directors of Beleave in accordance with the Company's stock option plan. Each option is exercisable to purchase one common share of the Company at $1.75 per common share. All options vest immediately and have a five-year term.
All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).
ABOUT BELEAVE INC. Beleave is a vertically-integrated Canadian cannabis company headquartered in Oakville, Ontario, that operates streamlined facilities throughout Canada to cultivate high-quality cannabis flower, oil, and extracts with funded capacity in excess of 150,000 kg per year.
Fully-licensed to cultivate and sell medical and recreational cannabis, Beleave is leading the way through research partnerships with universities to bridge the gap between science and tradition and to develop pharma-grade extracts and derivatives. Beleave is currently developing new product lines for October 2019 as the recreational market is expected to allow for food and beverage-based cannabis products.
Beleave is growing its storefront and online sales presence rapidly through its wholly-owned subsidiaries, Beleave Kannabis Corp. and Seven Oaks, which are licensed for medicinal and recreational sales respectively. The company's first retail location is opening this fall in Llyodminster, Saskatchewan. Beleave has also developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.
Through its majority ownership of Procannmed S.A.S., Beleave has access to 27 hectares of outdoor grow space and is fully licensed to cultivate, produce, extract and distribute medical cannabis in Colombia to capitalize on exports and the expanding Latin American market.
This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.
SOURCE Beleave Inc.
For further information: Investor Relations Contact: Richard Oyelowo, Phone: 1 (833) 375-9995, Email: [email protected]; Media Relations Contact: Grant McLeod, SVP, Regulatory Affairs and General Counsel, Phone: (416) 910-3401, Email: [email protected]